BeiGene Ltd
BGNE
Company Profile
Business description
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2023, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 50% of BeiGene’s revenue.
Contact
c/o Mourant Governance Services (Cayman) Limited
94 Solaris Avenue, Camana Bay
Grand CaymanKY1-1108
CYMT: +1 345 949-4123
E: ir@beigene.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
9,000
BeiGene Ltd News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,397.60 | 17.90 | 0.21% |
CAC 40 | 7,409.11 | 58.74 | 0.80% |
DAX 40 | 19,254.97 | 177.43 | 0.93% |
Dow JONES (US) | 42,052.19 | 288.73 | 0.69% |
FTSE 100 | 8,177.15 | 67.05 | 0.83% |
HKSE | 20,506.43 | 189.10 | 0.93% |
NASDAQ | 18,239.92 | 144.77 | 0.80% |
Nikkei 225 | 38,053.67 | 1,027.58 | -2.63% |
NZX 50 Index | 12,582.79 | 23.51 | 0.19% |
S&P 500 | 5,728.80 | 23.35 | 0.41% |
S&P/ASX 200 | 8,136.90 | 18.10 | 0.22% |
SSE Composite Index | 3,272.01 | 7.81 | -0.24% |